Prediction of intracellular exposure bridges the gap between target- and cell-based drug discoveryVisa övriga samt affilieringar
2017 (Engelska)Ingår i: Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, E-ISSN 1091-6490, Vol. 114, nr 30, s. E6231-E6239Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Inadequate target exposure is a major cause of high attrition in drug discovery. Here, we show that a label-free method for quantifying the intracellular bioavailability (F-ic) of drug molecules predicts drug access to intracellular targets and hence, pharmacological effect. We determined F-ic in multiple cellular assays and cell types representing different targets from a number of therapeutic areas, including cancer, inflammation, and dementia. Both cytosolic targets and targets localized in subcellular compartments were investigated. F-ic gives insights on membrane-permeable compounds in terms of cellular potency and intracellular target engagement, compared with biochemical potency measurements alone. Knowledge of the amount of drug that is locally available to bind intracellular targets provides a powerful tool for compound selection in early drug discovery.
Ort, förlag, år, upplaga, sidor
NATL ACAD SCIENCES , 2017. Vol. 114, nr 30, s. E6231-E6239
Nyckelord [en]
intracellular drug bioavailability, drug exposure, target engagement, published kinase inhibitor set, MAPK14
Nationell ämneskategori
Farmaceutiska vetenskaper
Identifikatorer
URN: urn:nbn:se:uu:diva-332843DOI: 10.1073/pnas.1701848114ISI: 000406189900026PubMedID: 28701380OAI: oai:DiVA.org:uu-332843DiVA, id: diva2:1155730
Forskningsfinansiär
Vetenskapsrådet, 2822Carl Tryggers stiftelse för vetenskaplig forskning Magnus Bergvalls StiftelseÅke Wibergs StiftelseScience for Life Laboratory - a national resource center for high-throughput molecular bioscienceEU, FP7, Sjunde ramprogrammet, 6075172017-11-092017-11-092018-07-30Bibliografiskt granskad